What topical therapy is recommended for atopic dermatitis?

Topical Treatment for Atopic Dermatitis

For most patients with atopic dermatitis, start with regular emollients/moisturizers combined with topical corticosteroids (TCS) of appropriate potency for active disease, then transition to maintenance therapy with either topical calcineurin inhibitors or newer nonsteroidal agents (PDE-4 inhibitors, JAK inhibitors) to prevent flares and minimize long-term TCS use. 1, 2

Foundation: Emollients and Basic Skin Care

All patients require consistent moisturizer use regardless of disease severity 3, 4. This is non-negotiable baseline therapy:

• Apply emollients liberally and frequently (ideally after bathing when skin is still damp) to restore the skin barrier and reduce transepidermal water loss 4
• Replace all soaps with soap-free cleansers or dispersible creams, as soaps strip natural lipids and worsen the already compromised barrier 4
• Avoid irritants: no wool directly on skin (use cotton instead), avoid temperature extremes, keep nails short 4

Active Disease Control: Anti-Inflammatory Agents

Topical Corticosteroids (First-Line for Flares)

TCS remain the mainstay for controlling active inflammation 4, 1. The evidence supporting their use is overwhelming with high certainty:

• Match potency to body site and severity:

  • Face, neck, genitals, intertriginous areas: low to medium potency only (Class VI-VII or Class IV-V)
  • Trunk and extremities: medium to high potency (Class III-V) for active disease
  • Thick, lichenified areas: high to very high potency (Class I-II) for short courses only 1

• Application frequency: Twice daily is traditional, but once daily may be sufficient for potent TCS 1

• Duration: Use until signs and symptoms are controlled, then do not simply stop—transition to maintenance therapy (see below) 1

Critical pitfall: Undertreatment due to steroid phobia is common. Educate patients that appropriate TCS use is safe and that avoiding treatment leads to worse outcomes 4.

Nonsteroidal Anti-Inflammatory Agents

These agents are strongly recommended and should be your preferred choice for maintenance therapy and sensitive areas 1, 2:

Topical Calcineurin Inhibitors (TCIs)

• Tacrolimus 0.1% and 0.03% ointment: Strong recommendation with high certainty evidence for moderate-to-severe AD 1
• Pimecrolimus 1% cream: Strong recommendation with high certainty evidence for mild-to-moderate AD 1
• Advantages: No atrophy risk, safe for face and intertriginous areas, can be used long-term
• Note on black box warning: Long-term safety studies show low absolute risk of lymphoma that is likely not clinically meaningful 1

Newer Topical Agents (Strong Recommendations)

The 2025 focused update provides strong recommendations for 2:

• Tapinarof cream: Aryl hydrocarbon receptor agonist
• Roflumilast cream: PDE-4 inhibitor
• Topical JAK inhibitors: Highly effective for active disease 1, 5

These newer agents are particularly valuable because they avoid both steroid side effects and the concerns associated with TCIs.

Maintenance Therapy to Prevent Flares

Once you achieve disease control, do not stop all treatment—this is a critical paradigm shift 6, 1:

• Topical corticosteroids: Apply 1-2 times per week to previously affected areas 6
• Topical calcineurin inhibitors: Apply 2-3 times per week to previously affected areas 6

This proactive maintenance approach significantly reduces flares and decreases overall TCS burden 6, 1.

Treatment Algorithm

1. All patients, always: Daily emollients + trigger avoidance + soap substitutes

2. Active mild-moderate disease:

   • Start: Medium-potency TCS (lower potency for face/folds) twice daily
   • Alternative for face/sensitive areas: Tacrolimus or pimecrolimus from the start
   • Continue until controlled (typically 1-2 weeks)

3. Active moderate-severe disease:

   • Start: High-potency TCS (appropriate to body site) once to twice daily
   • Consider newer agents (roflumilast, tapinarof, topical JAK inhibitors) as alternatives 2
   • Continue until controlled

4. Transition to maintenance (once controlled):

   • Switch to TCS 1-2×/week OR TCI 2-3×/week on previously affected areas
   • Continue daily emollients everywhere
   • This prevents the relapse cycle

5. If inadequate response after optimizing topical therapy:

   • Verify adherence and proper application technique
   • Rule out secondary infection (treat with appropriate antibiotics if present) 4
   • Consider contact dermatitis as complicating factor 3
   • Assess quality of life impact 3
   • Consider phototherapy or systemic therapy 3, 7

Special Considerations

Secondary infection: Common with crusting or weeping. Flucloxacillin is first-line for Staphylococcus aureus; use erythromycin for penicillin allergy 4. However, routine topical antimicrobials are not recommended for AD without overt infection 5.

Adjunctive therapies with limited evidence:

• Sedating antihistamines: Only useful short-term for severe pruritus disrupting sleep (sedative effect, not antihistamine effect) 4
• Non-sedating antihistamines: No value in AD 4
• Dilute bleach baths: Conditional recommendation 8, 5

Patient education is essential: Structured educational programs improve outcomes and should be considered adjunctive therapy 6.

The key to successful topical management is aggressive treatment of flares followed by consistent maintenance therapy, not the outdated approach of treating only when symptomatic and then stopping all treatment.